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Abstract: Sulforaphane (SFN), a phytochemical found in abundance in broccoli sprouts, potently 
induces a variety of antioxidant enzymes, and thereby protects cells from injury induced by various 
kinds of oxidative stresses. It has been suggested that both H. pylori infection and intake of 
non-steroidal anti-inflammatory drugs (NSAIDs) induce chronic oxidative stress in gastrointestinal 
(GI) mucosa, thereby causing mucosal injury in the GI tract. Therefore, it would be a reasonable 
assumption that SFN protects GI mucosa against oxidative injury induced by H. pylori or NSAIDs. In 
this review, we report our recent data on the effects of SFN on H. pylori-induced gastric mucosal 
inflammation and NSAID-induced small intestinal injury. Our data from the H. pylori infection 
study clearly demonstrated that SFN inhibited H. pylori viability both in vitro and in vivo, and 
mitigated H. pylori-induced gastritis in mice and humans. Similarly, our study on NSAID-induced 
small intestinal injury showed that SFN not only mitigated aspirin-induced injury of small intestinal 
epithelial cells in vitro, but also ameliorated indomethacin-induced small intestinal injury in mice in 
vivo. These data strongly suggest that SFN contributes to the protection of GI mucosa against 
oxidative injury induced by H. pylori or NSAIDs.       
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Introduction 
 Sulforaphane (SFN), an abundant antioxidant phytochemical found in 
broccoli sprouts (BS), potently induces a variety of antioxidant enzymes, which 
protect cells and organs against various kinds of oxidative stresses [1]. Recent 
studies have shown the antibacterial activity of SFN against Helicobacter pylori (H. 
pylori) in vitro [2]. We have recently shown that SFN induces antioxidant enzymes 
in the gastro-intestinal (GI) tract of mice, and protects GI mucosa against injuries 
induced by H. pylori and NSAIDs [3-5]. Our studies show that SFN not only 
enhances the antioxidant activity of GI mucosa, but also demonstrates antibacterial 
activity against H. pylori in gastric mucosa and anaerobic bacteria in the small 
intestine of mice [5]. We have conducted clinical trials with H. pylori-infected 
human subjects who consume BS, and have shown that SFN clearly inhibits H. 
pylori activity and mitigates H. pylori-induced gastritis [4]. This review introduces 
our recent data on the protective effects of SFN, which demonstrate that SFN 
prevented H. pylori- and NSAID-induced GI mucosal injury.  
 
Role of SFN in Protection of the Cells Against Oxidative Stress 
     It has been suggested that environmental factors, especially dietary factors, 
are more important in the development of GI cancer than genetic factors [6,7]. 
Recent studies have clearly associated the development of gastric cancer not only 
with H. pylori infection [8,9], but also with the intake of a high salt diet [10,11]. In 
contrast, it has also been reported that daily intake of fruits and vegetables 
decreased the risk of developing GI cancers [6,12]. However, the mechanisms by 
which intake of fruits and vegetables decreased the risk of GI cancers were not 
clarified until recently. It is naturally important to identify the protective 
substances from the various phytochemicals in fruits and vegetables. Furthermore, 
it is necessary to clarify the mechanisms by which each substance protects the GI 
tract against oxidative injury. Finally, the effects of such substances on human 
health should be examined through well-designed clinical trials.  
     SFN has been studied extensively in the past two decades, and several studies 
have suggested the possibility that SFN may contribute to cancer chemoprotection 
[13]. SFN, a member of the isothiocyanate (ITC) family, is abundant in cruciferous 
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vegetables, in particular broccoli sprouts (BS) [13,14]. Previous studies have shown 
that the unique molecular functional group -N=C=S is common to ITCs, which 
accounts for the pungency of these vegetables [15] (Fig 1). Different ITCs have been 
reported in a variety of foods. For example, Wasabi and mustard oils are rich in allyl 
ITCs [15]. Phenethyl ITC and 4-(methylthio)-3-butenyl ITC are found abundantly in 
Daikon and Cresson, respectively [16]. As previously stated, BS are rich in SFN. 
SFN potently induces various antioxidant (or phase 2) enzymes, such as glutathione 
S-transferase (GST), heme oxygenase-1 (HO-1), and NAD(P)H: quinone 
oxidoreductase 1 (NQO1), via Nf-E2 related factor 2-Kelch-like ECH-associated 
protein 1 (Nrf2-Keap1)-dependent pathways (17), thereby enhancing the 
antioxidant activity of the cells in the GI tract [4,5] (Fig 2).  
     In raw BS, SFN exists in the biologically inactive form of sulforaphane 
glucosinolates (SGS) [14]. The transformation of SGS to SFN occurs during the 
chewing process, where SGS is subjected to the action of myrosinase, also a 
component of BS [14]. SGS is also transformed to SFN in the intestinal lumen, by 
myrosinase of the intestinal microflora [14]. As previously stated, SFN upregulates 
phase 2 enzymes via Nrf2-Keap1-dependent mechanisms [17]. Under basal 
conditions, Nrf2 proteins are located in the cytoplasm and are biologically inactive 
as Nrf2 is bound to the Keap1 protein. Following exposure of the cells to oxidative 
stresses or SFN, Nrf2 proteins become dissociated from Keap1 and translocate into 
the nucleus. After entering the nucleus, Nrf2 protein binds to the antioxidant 
response element, and upregulates expression of a variety of xenobiotic and 
antioxidant enzymes [18-20] (Fig 2). It has been shown that induction of the phase 2 
enzymes by SFN lasts almost for 72 h [17]. In addition to activation of the 
Nrf2-Keap1 pathway within cells, SFN has also been shown to inhibit H. pylori 
viability in vitro; these effects were demonstrated in both the 
clarithromycin-sensitive and resistant strains [2]. Furthermore, other studies have 
shown that SFN decreases colonization in mice stomach ex vivo [21], and in a small 
number of human cases [22].  
     Based on these results, we aimed to determine if oral intake of SFN 
contributed to the protection of GI mucosa against GI diseases induced by oxidative 
stresses, such as those induced by H. pylori and NSAIDs. 
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Roles of SFN in Protection Against H. pylori-Induced Gastric Mucosal 
Inflammation 
     H. pylori infection induces chronic oxidative stress in gastric mucosa, which 
eventually induces gastric cancer. However, SFN has been shown to mitigate 
various kinds of oxidative stresses. In this study, we aimed to determine if SFN 
inhibited H. pylori activity in vitro, and if SFN mitigated H. pylori-induced 
oxidative injury in gastric mucosa in mice and humans in vivo. 
 1. Effect of SFN on Urease Activity and H. pylori Viability in vitro 
     In this series of experiments, we examined whether SFN showed direct 
antibacterial activity against H. pylori in vitro [23]. The H. pylori strain Sydney 
Strain-1 (SS-1) was used in this study. The viability of H. pylori was determined by 
evaluating the number of colony forming units (CFU) after incubation of the H. 
pylori in the absence or presence of various concentrations of SFN for 3 h. The 
urease activity of H. pylori was assessed by measurement of the concentration of 
ammonia released into the medium during incubation with 5 mM urea for 1 h. The 
effects of SFN on urease activity and viability of H. pylori were examined at 
ambient pH 7.4 in vitro. At doses from 1-100 µg/mL, SFN dose-dependently 
decreased urease activity and viability of H. pylori (Fig 3). These results suggest 
that SFN shows antibacterial activity against H. pylori in vitro.  
 2. Effect of SFN on H. pylori Colonization and Gastric Mucosal Inflammation in H. 
pylori-Infected Mice in vivo 
     Based on the in vitro experimental data, we conducted the next series of 
studies to determine if SFN inhibited colonization of H. pylori and mitigated 
inflammation in H. pylori-infected gastric mucosa in mice in vivo.   
     Gastric mucosal infections with H. pylori Sydney Strain-1 were established in 
6-week-old female C57BL/6 mice of both wild-type (Nrf2+/+) and Nrf2 knockout 
(Nrf2-/-) strains by inoculation with 5 × 107 CFU of H. pylori [24]. The H. 
pylori-infected mice were fed a high-salt diet (7.5% NaCl) for 2 months in order to 
exacerbate inflammation in gastric corpus mucosa [11]. The wild-type and Nrf2-/- 
mice were fed the homogenized BS (+BS), or no BS (−BS). Approximately 3 
µmol/mouse/day of SGS was administered to the +BS group. Eight weeks later, all 
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mice were sacrificed. Gastric mucosal preparations were fixed with formalin, 
stained with hematoxylin and eosin, and examined using light microscopy. The 
degree of gastric mucosal inflammation was measured using the updated Sydney 
system [25]. Activities of the gastric mucosal phase 2 detoxification enzymes, NQO1 
and GST, were measured by ELISA. H. pylori colonization of mice gastric mucosa 
was assessed as described in our previous report [4].  
  1) Effect of BS Treatment on Gastric Mucosal Inflammation 
   Morphological examination by light microscopy of the gastric mucosae in H. 
pylori-infected Nrf2+/+ mice showed massive infiltration of inflammatory cells in 
the mice not receiving BS, while the mice fed BS showed less inflammation (Fig 4). 
   Following the administration of BS, activation of the antioxidant enzymes NQO1 
and GST increased significantly in Nrf2+/+, but not Nrf2-/- mice, as expected (26). 
In agreement with these findings, inflammation of the gastric corpus mucosa in H. 
pylori-infected mice was substantially attenuated by treatment with BS in Nrf2+/+, 
but not in Nrf2-/- mice (Fig 4, Fig 5).  
  2) Effect of BS Treatment on H. pylori Colonization   
  BS treatment induced an almost 2-log reduction in H. pylori colonization in 
wild-type mice but not in Nrf2-/- mice (Fig. 5), thus confirming the integral role of 
the SFN-induced Nrf2 activation in protection against H. pylori-induced gastric 
inflammation.  
 3. Effect of Daily Intake of SFN-Rich BS on H. pylori Infection in Human Subjects 
     Based on the in vivo experimental data from H. pylori-infected mice, we 
conducted the next experiments to determine if daily intake of SFN-rich BS 
mitigated H. pylori-induced gastritis in human subjects.  
    Fifty H. pylori-positive volunteers, whose endoscopy showed no abnormalities 
other than gastritis, were randomized to either the BS group (n=25) or the alfalfa 
sprouts (AS) group (n=25). In this study, AS were used as the placebo, since they do 
not contain SGS or other isothiocyanates (Fig 6). Subjects were instructed to 
consume 70 g/day of SGS-rich 3-day-old BS (Broccoli Super Sprout®, Murakami 
Pharm Ltd, Japan) for 8 weeks; these sprouts were validated to have an SGS 
content of approximately 6 µmol/g [27, 28]. Subjects in the AS (placebo) group were 
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instructed to consume an equivalent amount of AS for 8 weeks. All participants 
were required to attend the hospital for collection of blood and stool samples at 0, 4, 
8, and 16 weeks (eight weeks after the completion of the intervention); the dates 
corresponded to study days 0, 28, 56, and 112, respectively. Stool samples were 
analyzed for H. pylori stool antigen (HpSA) using an HpSA-ELISA kit from 
Meridian Bioscience, Inc., as previously described [29]. Serum pepsinogens I and II 
(PGI and PGII) were measured in blood samples collected from volunteers at these 
same time points, and the PGI/PGII ratio was computed [30, 31]. All test results 
were compared using a Student's t-test. Error bars on all figures represent ±1 SD 
from the mean. 
     The study protocol (outlined in Fig. 6) randomized 50 subjects to daily 
consumption of either 70 g of BS or a placebo (AS). The mean age of subjects at 
randomization was 54.5 years. There were more female (n=28) than male (n=19) 
subjects, but there was no difference in pre-intervention H. pylori infection and 
inflammation status for the two groups (Table 1). Two subjects in the AS group 
dropped out during the intervention period owing to acute viral infection. Thus, the 
data obtained from 25 subjects in the BS group and 23 in the AS group were 
analyzed.  
  1) Effects of BS/AS Treatment on Serum PGI and PGII  
     During the intervention period, significant reductions in both PGI and PGII (P 
< 0.05) compared with baseline levels were only observed in the BS group, and these 
returned to baseline values 2 months after the intervention. The ratio of PGI to 
PGII, used as a more robust indicator of changes in gastric inflammation (31), 
increased significantly (P < 0.05) during the intervention in the BS group (Fig. 7).  
  2) Effects of BS/AS Treatment on HpSA  
     The HpSA levels measured in the BS intervention arm were significantly 
lower (P < 0.05) during the intervention than at baseline, and returned to baseline 
levels (P < 0.05) at 16 weeks (2 months after intervention). The placebo group 
receiving AS showed no significant change in HpSA (Fig.8). Of the 25 subjects in the 
BS treatment group, eight subjects had HpSA values below the cutoff (0.100) at the 
end of the 8-week BS treatment period. In six of these subjects, the HpSA values 
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became positive again at 8 weeks after cessation of BS consumption, and the HpSA 
values of the remaining two subjects became positive again, 6 months after 
intervention, thus indicating that BS treatment reduced H. pylori colonization but 
did not result in complete eradication. 
4. Discussion 
     This study was designed to determine whether regular dietary consumption of 
BS, which is rich in the SFN precursor SGS, inhibited H. pylori colonization and 
attenuated inflammation in the gastric mucosa of mice and humans.  
     In this study, we first established that oral intake of BS decreased gastric 
mucosal inflammation in vivo in a well-established H. pylori-infected animal model. 
Oral dosing of animals in this model (approximately 3 µmol/mouse/day) was 
consistent with the SFN dosages in a variety of other mouse experiments 
investigating carcinogenesis [21,32-35].  
     Second, the findings strongly suggest that mitigation of gastritis by SFN was 
at least partially due to the induction of antioxidant enzymes via the Nrf2 signaling 
pathway. SFN is a well-known activator of antioxidant enzymes and we have shown 
that these enzymes are upregulated in BS-treated animals. 
     Third, we determined that H. pylori colonization decreased in SFN-treated 
wild-type mice but not in Nrf2-/- mice. This in vivo finding suggests that SFN may 
have a direct antibiotic effect on the level of H. pylori colonization. The primary 
effect may occur via the upregulation of the host's systemic protection against 
oxidative stress and inflammation, which results in reduced H. pylori colonization. 
The mechanisms for the detoxification effects of SFN have been studied extensively 
[1, 17, 36-38]. SFN induces cytoprotective, antioxidant, and anti-inflammatory 
enzymes via the transcription factor Nrf2, which activates the genes that control 
these endogenous protective responses [20]. H. pylori infection generates a variety 
of reactive oxygen species within the mucosa that enhance gastric mucosal injury 
and inflammation. Our data show that H. pylori-induced gastritis in human 
subjects is mitigated by BS treatment. The data suggest that this effect is induced 
either by the inhibition of H. pylori colonization (in vitro, SFN is a potent antibiotic 
against H. pylori), the upregulation of Nrf2-dependent antioxidant enzyme activity 
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(a number of in vitro, animal, and clinical studies have reported this), or by a 
combination of these two factors. Nonetheless, the SFN-induced enhancement of 
Nrf2-dependent antioxidant enzyme activity in gastric mucosal cells reduced 
reactive oxygen species from gastric mucosa, which resulted in the mitigation of H. 
pylori infection-induced gastritis. 
     Fourth, daily intake of BS (70 g) for 2 months decreased serum levels of PGI 
and PGII and increased the PGI/PGII ratio during the 2-month intervention period, 
which was consistent with clinical observations correlating to increased PGI/PGII 
ratio with reduced inflammation of gastric mucosa [30, 31]. We also measured 
reductions in HpSA (an indicator of recent infection) after the intake of BS. All 
biomarkers returned to baseline levels after the intervention was discontinued. 
     In summary, our data on H. pylori-infected mice and humans clearly 
suggested that SFN may have a direct antibacterial effect on H. pylori, leading to 
reduced gastritis, and a systemic effect by increasing the antioxidant response. It is 
not possible to determine the relative contributions of these two mechanisms from 
this study; however, in light of other evidence which suggests a strong anti-H. pylori 
effect of SFN in vitro [2], the findings in this study suggest that SFN has promise 
both as an antibacterial agent directed against H. pylori and a dietary preventive 
agent against the development of human gastric cancer. 
 
Roles of SFN in Protection of the Small Intestine against Aspirin/NSAID-induced 
Mucosal Damage 
     The current prevalence of the prescription of aspirin and/or other NSAIDs to 
prevent cardiovascular events and relieve pain from osteoarthritis [39-41] is rising. 
It is well-established that aspirin and/or NSAIDs frequently cause peptic ulcer 
disease and bleeding from the upper GI tract. In order to prevent aspirin and/or 
NSAID-induced GI mucosal injuries, potent acid inhibitors that significantly 
ameliorate these injuries, such as proton pump inhibitors (PPI), have been 
prescribed [42]. However, recent advances in capsule video endoscopy have revealed 
that the ulcers caused by aspirin and/or NSAIDs were not only localized to the 
upper GI tract, but also the small intestine [43-45]. Studies in human volunteers 
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using capsule endoscopy have shown PPIs do not offer effective protection of the 
small intestinal mucosa against injury [46]. A recent study in rat has shown that 
PPI exacerbates NSAID-induced ulcers in the small intestine [47]. Although 
misoprostol has some beneficial effects on NSAID-induced gastrointestinal ulcers 
[48,49], it causes several adverse reactions such as abdominal pain, diarrhea, and 
abortion [50]. A recent study in rats has shown that geranylgeranylacetone (GGA), 
a mucosal protective agent known to induce HSP70 in gastrointestinal mucosa, 
prevents small intestinal mucosa from injury induced by loxoprofen [51]. A few 
clinical trials using a small number of human volunteers have shown that 
aspirin/NSAID-induced small intestinal injuries detected by capsule video 
endoscopy are ameliorated by GGA [52] or rebamipide [53,54], both of which have 
been used as gastric mucosal protective agents. Currently, however, there is no 
direct evidence that such agents are clinically effective for protection against 
NSAID-induced small intestinal ulcers. In the present study, we investigated the 
phytochemical sulforaphane (SFN) as a possible candidate drug for prevention of 
NSAID-induced small intestinal injuries. Since activation of antioxidant enzymes 
by SFN persists for 48-72 h, the protective effects of SFN against oxidative stress 
may be more potent than those of other antioxidant substances are. As NSAIDs 
induce oxidative stress in GI mucosa, it is reasonable to assume that SFN may be 
useful for protection of the small intestinal mucosa against oxidative stress induced 
by NSAIDs. Recent studies have shown that NSAID exaggerates small intestinal 
injuries, at least in part by causing overgrowth of anaerobic bacteria in the 
intestinal lumen [55,56]. Therefore, it seems reasonable to assume that SFN may 
inhibit colonization of anaerobic bacteria in the intestinal lumen, thereby 
preventing invasion of the bacteria into the mucosa and consequently mitigating 
small intestinal injuries. Therefore, we decided to determine if SFN could protect 
small intestinal mucosa from NSAID-induced small intestinal injuries. 
 1. Role of SFN in Protection of IEC6 cells against Aspirin-induced Injury in vitro 
     IEC6 cells, derived from rat small intestinal mucosa, were incubated with or 
without various doses of SFN. After incubation for 12 h, the cells were treated with 
various dosages of aspirin. In some experiments, the effect of zinc 
protoporphyrin-IX (ZnPP), an inhibitor of HO-1, was also examined. The viability of 
 10 
 
the IEC6 cells was assessed by the measurement of 3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide (MTT) incorporation into the cells. Expression of 
HO-1 protein by IEC6 cells were evaluated by western blot analysis, using a 
polyclonal antibody to HO-1 (Hsp 32) as the primary antibody.  
  1) Effects of Aspirin on Viability of IEC-6 Cells 
     Aspirin, at doses between 10 to 40 mM, dose-dependently decreased viability 
of IEC-6 cells after incubation for 12 h (data not shown). Therefore, in the next 
series of experiments, we decided to use 20 mM aspirin, which is a submaximal dose 
to cause injury in IEC-6 cells. 
  2) Effect of Pretreatment with SFN on Aspirin-Induced Injury in IEC6 Cells  
     We confirmed that incubation of the cells with 5 µM SFN for 6 h did not cause 
injury to IEC-6 cells, but did induce HO-1 expression, as discussed later. Therefore, 
we decided to use 5 µM SFN in the following experiments. In this series of 
experiments, the cells were initially exposed to 5 µM SFN for 6 h, followed by 
incubation without SFN for a further 12 h. Then, the cells were exposed to various 
doses of aspirin. Pretreatment of the cells with SFN attenuated the 20 
mM-aspirin-induced death of IEC6 cells (Fig 9). 
  3) Effect of Pretreatment with SFN on HO-1 Expression in IEC-6 Cells 
     The cells were exposed to 5 µM SFN for 6 h, followed by incubation without 
SFN for a further 12 h. Western blot analysis showed that HO-1 expression in 
IEC-6 cells increased significantly after incubation with SFN for 6 h, and the effects 
persisted at 12 h after removal of SFN from the medium (Fig 10). These results 
indicated that pretreatment with SFN upregulated HO-1 expression, and that the 
effect persisted during the subsequent exposure to aspirin. 
  4) Effects of HO-1 Inhibitor on the Protective Effects of SFN Against 
Aspirin-Induced Cell Injury  
     The cells were exposed for 6 h to 5 µM SFN in combination with 0.1 µM ZnPP, 
an HO-1 inhibitor, followed by incubation without SFN and ZnPP for a further 12 h. 
After this, the cells were exposed to 20 mM aspirin. Co-administration of ZnPP with 
SFN tended to attenuate the protective effects of SFN on the aspirin-induced IEC6 
cell injury (Fig 11), which indicated that HO-1 may contribute to the protective 
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effect of SFN against aspirin-induced cell injury. Further experiments are required 
to confirm this assumption. 
 2. Role of SFN in Protection of the Small Intestinal Mucosa against Indomethacin 
(IND)-Induced Injury in vivo 
     Male ddY mice aged 7 weeks were used in this study. Small intestinal injuries 
were induced by two subcutaneous injections of IND (20 mg/kg), as described 
elsewhere [57]. The time interval between the first and second IND injections was 
24 h. The mice were sacrificed 6 h after the second IND injection. The small 
intestinal mucosa was carefully examined for lesions under a dissecting microscope. 
MPO activity was measured by a previously described method [58]. Vascular 
permeability was assessed by measuring the amount of leakage of Evans blue into 
the small intestinal tissue, after intravenous injection of the dye at 1 h before 
sacrifice [59]. Enterobacteria within the small intestinal mucosa were quantified by 
a previously described method [60]. In brief, the homogenates of the small intestinal 
mucosa were placed on Gifu anaerobic medium agar and incubated for 24 h under 
anaerobic conditions. The number of enterobacteria was expressed as log CFU/g of 
tissue. SGS was orally administered at 0.5 h before and 6 h after the administration 
of IND. 
  1) Effects of IND on Small Intestinal Mucosae 
     Treatment of the mice with IND induced small bowel shortening, increases in 
the lesion score (Fig 12), vascular permeability (Fig 13), and MPO activity (Fig 14); 
this suggested that treatment with IND caused small intestinal mucosal injury in 
mice.  
  2) Effect of SGS on the IND-induced Injuries in Small Intestinal Mucosa 
     Oral administration of SGS did not affect the lesion score, vascular 
permeability, or mucosal MPO activity in the IND-untreated negative control mice. 
In contrast, pretreatment of the mice with orally administrated SGS inhibited the 
increases in lesion score, vascular permeability, and MPO activity in the 
IND-treated mice (Fig. 12, 13, 14), suggesting that SGS attenuates IND-induced 
small intestinal injuries in mice. 
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  3) Effect of SGS on Anaerobic Enterobacterial Count in Small Intestinal Mucosa 
of IND-Treated Mice  
     Oral administration of SGS significantly inhibited the overgrowth of anaerobic 
enterobacteria in IND-untreated mice. Furthermore, pretreatment of the mice with 
SGS completely abolished the increase in the overgrowth of anaerobic 
enterobacteria the IND-treated mice (Fig. 15). 
3. Discussion 
     The data from in vitro experiments show adaptive cytoprotection by SFN 
against aspirin in IEC6 cells. We have confirmed that SFN enhanced HO-1 
expression in small intestinal mucosa in this experimental system. Furthermore, 
the present finding that the protective effects of SFN are mitigated by an HO-1 
inhibitor, ZnPP, strongly support our hypothesis that SFN affords adaptive 
cytoprotection against aspirin via Nrf2-dependent pathways. It has been reported 
that aspirin causes oxidative stress in cells by damaging mitochondrial respiration 
[61]. Thus, we assume that pretreatment with SFN enhances the antioxidant 
system in the cells, thereby eliminating oxidative stress induced by aspirin. Our 
data from in vivo studies also showed that pretreatment with orally administrated 
SGS protects small intestinal mucosa against IND-induced injury, suggesting that 
SFN also provides adaptive cytoprotection to the small intestinal mucosa against 
IND-induced injury in vivo. The present study showed that SFN enhanced HO-1 
expression in vitro. We also confirmed that SGS treatment enhanced HO-1 
expression in small intestinal mucosa in mice in vivo (unpublished observations). In 
addition, the present study also indicated that SGS inhibited invasion of anaerobic 
enterobacteria into the mucosa in vivo. Thus, it seems reasonable to assume that 
SFN and/or SGS have twofold beneficial effects on small intestinal mucosa against 
IND-induced small intestinal injury.  
     It has been reported that mild irritants protect gastric mucosa from the 
ensuing severe stress by induction of endogenous prostaglandins, a phenomenon 
named “adaptive cytoprotection” by Andre Robert [62]. However, a number of other 
studies have shown that “adaptive cytoprotection” cannot be explained by 
endogenous prostaglandins. More recent studies have suggested possible candidates 
for adaptive cytoprotection. For example, it has been shown that mild stress induces 
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heat shock proteins in gastric mucosa, thereby protecting the mucosa from severe 
stress, which also accounts for “adaptive cytoprotection” [63]. Alternatively, 
Yamamoto et al. have recently demonstrated that mild oxidative stress induces 
antioxidant enzymes via the Nrf2-Keap1 system, which strengthen antioxidant 
activity of the cells against more severe oxidative stress [64]. Since NSAIDs cause 
oxidative stress in cells [62,65], it is reasonable to assume that SFN protects GI 
mucosa from NSAID-induced oxidative stress by strengthening Nrf2-Keap1 
mediated antioxidant systems. Our findings strongly support this hypothesis [5]. In 
contrast, recent studies have suggested a role of anaerobic enterobacteria in the 
pathogenesis of NSAID-induced intestinal mucosa [47,55,56], which indicated that 
anaerobic bacteria generally exacerbate NSAID-induced injury in the small 
intestine, although the exact mechanisms remain to be elucidated. As SFN shows 
antibacterial activity against H. pylori [1,4], it may be possible that SFN also 
demonstrates antibacterial activity against anaerobic enterobacteria in the small 
intestine, thereby ameliorating NSAID-induced small intestinal injury. In 
conclusion, we propose that SFN is a strong candidate for the prevention or 
treatment of aspirin/NSAID-induced small intestinal ulcers in clinical practice. 
Clinical trials of the effects of SFN on NSAID-induced injury in the small intestine 
of humans should be conducted imminently. 
     In summary, our data suggest that the activation of Nrf2-Keap1 dependent 
antioxidant enzyme activity by SFN contributed to protection of small intestinal 
mucosa against NSAID-induced oxidative stress. Our data also indicated that SFN 
ameliorates NSAID-induced small intestinal injuries by suppression of the invasion 
of anaerobic bacteria into the mucosa. 
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Figure Legends 
Figure 1. Broccoli Sprouts Contain High Concentration of Sulforaphane (SFN) 
SFN, a member of the isothiocyanate (ITC) family, is abundant in cruciferous 
vegetables, especially broccoli sprouts (BS). (A) Fifty grams of raw BS contain 128 
mg of sulforaphane glucosinolate, a precursor of SFN. (B) SFN possesses -N=C=S, 
which is a common chemical structure found in the ITC family. This molecular 
structure accounts for the pungency of the cruciferous vegetables. 
 
Figure 2. Sulforaphane (SFN) Enhances Antioxidant Activity via Nrf2-Keap1 
System. 
SFN potently induces various antioxidant (or phase 2) enzymes, such as glutathione 
S-transferase (GST), heme oxygenase-1 (HO-1), and NAD(P)H: quinone 
oxidoreductase 1 (NQO1), via Nf-E2 related factor 2 (Nrf2) - Kelch-like 
ECH-associated protein 1 (Keap1) dependent pathways. These are responsible for 
the enhanced antioxidant activity of the cells. 
 
Figure 3. Sulforaphane (SFN) Markedly Inhibits Urease Activity and Viability of H. 
pylori 
The H. pylori strain Sydney Strain-1 (SS-1) was used in this study. The urease 
activity of H. pylori was assessed by measurement of the concentration of ammonia 
released into the medium during a 1-h incubation period with 5 mM urea. The 
viability of H. pylori was determined by the number of colony forming units (CFU) 
after incubation of the H. pylori in the absence or presence of various concentrations 
of SFN for 3 h. The effects of SFN on H. pylori viability and urease activity were 
examined at ambient pH 7.4 in vitro. At doses of 1-100 µg/mL, SFN 
dose-dependently decreased the viability of H. pylori. The representative trace in 
left panel shows that SFN dose-dependently inhibits H. pylori urease activity. The 
right panel shows that SFN dose-dependently decreased H. pylori viability. n: 
number of experiments. *P < 0.05; significant difference from the corresponding 
values in the absence of SFN. 
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Figure 4. Broccoli Sprouts Markedly Attenuate Corpus Gastritis in H. pylori- 
infected Mice Fed High Salt Diet 
Gastric mucosal infections with H. pylori Sydney strain-1 were established in 
6-week-old female C57BL/6 mice of both the wild-type (Nrf2+/+) and knockout 
(Nrf-/-) mice by inoculation of 5 × 107 CFU of H. pylori [24]. The H. pylori-infected 
mice were fed for 2 months with a high-salt diet (7.5% NaCl) in order to exacerbate 
inflammation in gastric corpus mucosa. The mice were fed with the homogenized 
broccoli sprouts (+BS), or without BS (−BS). Approximately 3 µmol/mouse/day of 
SGS were administered into the +BS group. All the mice were sacrificed at 8 weeks 
later. Gastric mucosal preparations, fixed with formalin and stained with 
hematoxylin and eosin, were examined by light microscopy. 
A representative histology of gastric mucosa of the H. pylori-infected mice without 
BS treatment shows massive infiltration of inflammatory cells (upper panel), while 
the histology of the mice fed with BS shows less inflammation (lower panel). 
Scale bar: 200 µm. 
 
Figure 5. Broccoli Sprouts Attenuate Corpus Gastritis and Inhibits H. pylori 
Colonization in Nrf2+/+, but not in Nrf2-/- mice  
The wild-type (Nrf2+/+) and the Nrf2 knockout (Nrf2-/-) mice infected with H. pylori 
were fed with broccoli sprouts (BS) (+BS; ■), or without BS (-BS; □) (as described in 
Fig 4 legend). The degree of inflammation in gastric corpus mucosa was expressed 
as the inflammation score as defined in the updated Sydney system [25]. H. pylori 
colonization was expressed as the number of H. pylori colony forming units (CFU) 
after incubation of the mucosal homogenates in the specific medium for H. pylori 
culture, described in our previous report [4]. The left panel shows that feeding with 
BS significantly mitigated both the inflammation score (left panel) and the 
colonization (right panel) in Nrf2+/+, but not in Nrf2-/- mice (*P < 0.05; significant 
difference from the corresponding values in the absence of BS; n=number of 
animals).   
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Figure 6. Protocol for the Broccoli Sprouts Clinical Trial on H. pylori Infection 
Fifty H. pylori–positive volunteers were randomized to either the broccoli sprouts 
(BS) group (n=25), or the alfalfa sprouts (AS) group (n=25). In this study, AS was 
used as the placebo, since AS do not contain any sulforaphane glucosinolates (SGS), 
the precursor of SFN. Subjects were instructed to consume 70 g/day of either the 
SGS-rich 3-day-old BS that contains SGS of approximately 6 µmol/g dose [27, 28], or 
an equivalent amount of AS for 8 weeks. All participants were instructed to attend 
the hospital for collection of blood and stool samples at 0, 4, 8, and 16 weeks. Levels 
of serum pepsinogens I and II (PGI and PGII) were measured by a commercially 
available ELISA kit, and PGI/PGII ratios were calculated [30, 31]. Stool samples 
were analyzed for H. pylori stool antigen (HpSA) using a HpSA-ELISA kit, as 
previously described (29) All tests results were compared using a Student's t test for 
paired comparison. Error bars on all figures represent ±1 SD from the mean. 
 
Figure 7. Effect of Broccoli Sprouts (BS) and/or Alfalfa Sprouts (AS) on Serum 
Pepsinogen I/II Ratio 
There were significant reductions in both PGI and PGII compared with baseline 
levels during the 8-week intervention period in the BS group, and there was a 
return to baseline values at eight weeks after the intervention. Since the magnitude 
of the reduction in PGII was greater than PGI, the ratio of PGI to PGII (PGI/PGII) 
rose significantly during the intervention in the BS group, suggesting that BS 
treatment mitigates gastric inflammation. In contrast, there were no changes in 
PGI/PGII throughout the entire study period in AS group. Rectangular overlays 
represent means for each time period. n=number of participants.       
    P < 0.05; Significant difference from the corresponding values at week 0.             
    P <0.05; Significant difference from the corresponding values at week 8.   
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Figure 8. Effects of Broccoli Sprouts (BS) and/or Alfalfa Sprouts (AS) on H. 
pylori-Specific Stool Antigen (HPSA)  
There was a significant reduction in of H. pylori-Specific Stool Antigen (HpSA) 
compared with baseline levels during the 8-week intervention period in the BS 
group, and there was a return to baseline values at eight weeks after the 
intervention, suggesting that BS treatment reduces H. pylori colonization, but does 
not eradicate H. pylori completely. In contrast, there were no changes in the HpSA 
levels in the AS group, throughout the whole study period. Rectangular overlays 
represent means for each time period. n=number of participants.       
    P < 0.05; Significant difference from the corresponding values at week 0.             
    P <0.05; Significant difference from the corresponding values at week 8.   
 
Figure 9. Sulforaphane (SFN) attenuates Aspirin-Induced Injury in IEC6 Cells 
The cells were initially exposed to 5 µM SFN for 6 h, followed by incubation without 
SFN for a further 12 h. The cells were subsequently exposed to various doses of 
aspirin. Pretreatment with 5 µM SFN attenuated aspirin (20 mM)-induced decrease 
in the viability of IEC6 cells. The data are expressed as Mean ± SEM. n= number of 
experiments; * P < 0.05; statistically significant difference from the corresponding 
value in the absence of SFN.  
 
Figure 10. Sulforaphane (SFN) Up-Regulates Heme Oxygenase (HO)-1 Expression 
in IEC6 Cells   
The cells were exposed to 5 µM SFN for 6 h, followed by incubation without SFN for 
a further 12 h. Western blot analysis shows that HO-1 expression increased 
significantly at 6 h after incubation with 5 µM SFN, and that this effect still persists 
at 12 h after removal of SFN from the medium. The data are expressed as Mean ± 
SEM. n=number of experiments; * P < 0.05; significant difference from the 
corresponding value in the absence of SFN.  
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Figure 11. ZnPP, an Heme Oxygenase (HO)-1 inhibitor, Tends to Attenuate  
Protective Effects of Sulforaphane (SFN) against Aspirin-Induced Injury of IEC6 
Cells  
The cells were initially exposed for 6 h to 5 µM SFN in combination with 0.1 mM 
ZnPP, an HO-1 inhibitor, followed by incubation without either agent for a further 
12 h. The cells were then exposed to 20 mM aspirin. Co-administration of ZnPP with 
SFN attenuated the protective effects of SFN on aspirin-induced IEC6 cell injury. 
The data are expressed as Mean ± SEM. n=number of experiments; a, P < 0.05; 
significant difference from the corresponding value in the absence of SFN; b, P = 
0.09; difference from the corresponding value in the absence of ZnPP.  
 
Figure 12. Oral Intake of Sulforaphane Glucosinolates (SGS) Ameliorates 
Indomethacin (IND)-Induced Injury of Small Intestine 
Oral administration of 17 mg/kg SGS did not affect the lesion score in the 
IND-untreated mice. In contrast, pretreatment with SGS inhibited the increase in 
the lesion score in the IND-treated mice. The data are expressed as mean ± SEM. 
n=number of experiments; a, P<0.05; significant difference from the corresponding 
value without IND; b, P<0.05; significant difference from the corresponding value 
without SGS.  
 
Figure 13. Oral Intake of Sulforaphane Glucosinolates (SGS) Ameliorates 
Indomethacin (IND)-Induced Increase in Mucosal Permeability of Small Intestine 
in Mice 
  Oral administration of 17 mg/kg SDS did not influence the mucosal content of 
Evans blue in the IND-untreated negative control mice. In contrast, pretreatment of 
with SGS inhibited the increase in the mucosal content of Evans blue in the 
IND-treated mice. The data are expressed as mean ± SEM. n=number of 
experiments; a, P < 0.05; significant difference from the corresponding value 
without IND; b, P < 0.05; significant difference from the corresponding value 
without SGS.  
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Figure 14. Oral Intake of Sulforaphane Glucosinolates (SGS) Blocks Indomethacin 
(IND)-Induced Increase in Myeloperoxidase (MPO) Activity of Small Intestinal 
Mucosa in Mice 
  Oral administration of 17 mg/kg SDS did not affect the mucosal MPO activity in 
the IND-untreated mice. In contrast, pretreatment with SGS inhibited the increase 
in the mucosal MPO activity in the IND-treated mice. The data are expressed as 
Mean ± SEM. n=number of experiments; a, P < 0.05; significant difference from the 
corresponding value without IND; b, P < 0.05; significant difference from the 
corresponding value without SGS.  
 
Figure 15. Oral Intake of Sulforaphane Glucosinolates (SGS) Inhibits Indomethacin 
(IND)-Induced Increase in Anaerobic Bacteria of Small Intestinal Mucosa in Mice 
Oral administration of 17 mg/kg SDS significantly inhibited amount of mucosal 
anaerobic enterobacteria in the IND-untreated mice. Pretreatment of the mice with 
SGS totally abolished the increase in the mucosal amount of anaerobic 
enterobacteria the IND-treated mice. The data are expressed as Mean ± SEM. 
n=number of experiments; a, P < 0.05; significant difference from the corresponding 
value without IND; b, P < 0.05; significant difference from the corresponding value 
without SGS.  
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Fig 11.    
ZnPP, an HO-1 inhibitor, tends to Attenuate Protective Effect of SFN 
against Aspirin-Induced Injury of IEC6 Cells
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Fig 12.   
Oral Intake of SGS Ameliorates IND-Induced Injury of the Small Intestine
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Fig 13.   Oral Intake of SGS Ameliorates IND-Induced 
Increase in Mucosal Permeability of Small Intestine in Mice
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Fig 14.   Oral Intake of SGS Blocks IND-Induced Increase in MPO 
Activity of Small Intestinal Mucosa in Mice
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Fig 15.   Oral Intake of SGS Inhibits IND-Induced Increase in    
Anaerobic Bacteria of  Small Intestinal Mucosa in Mice
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